Ahn, Myung-Ju

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Kim, Y., Lee, B., Shim, J. H., Lee, S.-H., Park, W.-Y., Choi, Y.-L., Sun, J.-M., Ahn, J. S., Ahn, M.-J., & Park, K. (2019) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 174

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Barlesi, F., Scherpereel, A., Gorbunova, V., Gervais, R., Vikström, A., Chouaid, C., Chella, A., Kim, J. H., Ahn, M. J., Reck, M., et al. (2014) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 165

SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells

Han, K. Y., Kim, K.-T., Joung, J.-G., Son, D.-S., Kim, Y. J., Jo, A., Jeon, H.-J., Moon, H.-S., Yoo, C. E., Chung, W., et al. (2018) · Genome Research

Single-cell and spatial transcriptomicsGenomics and Phylogenetic Studies

Cited by 143

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Sands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 130

Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer

Heymach, J. V., Ruiter, G., Ahn, M.-J., Girard, N., Smit, E. F., Planchard, D., Wu, Y.-L., Cho, B. C., Yamamoto, N., Sabari, J. K., et al. (2025) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 118

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Drilon, A., Chiu, C.-H., Fan, Y., Cho, B. C., Lu, S., Ahn, M.-J., Krebs, M. G., Liu, S. V., John, T., Otterson, G. A., et al. (2022) · JTO Clinical and Research Reports

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 113

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Ahn, M.-J., Lisberg, A., Goto, Y., Sands, J., Hong, M. H., Paz-Ares, L., Pons-Tostivint, E., Pérol, M., Felip, E., Sugawara, S., et al. (2025) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 66

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer

Oxnard, G. R., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Yu, H. A., Saka, H., Horn, L., Goto, K., Ohe, Y., Cantarini, M., et al. (2015) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 46

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Lee, J. Y., Sun, J.-M., Lim, S. H., Kim, H. S., Yoo, K. H., Jung, K. S., Song, H.-N., Ku, B. M., Koh, J., Bae, Y.-H., et al. (2016) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 36

AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): preclinical evidence and clinical cases

Kim, D.-W., Yang, J. C.-H., Chen, K., Cheng, Z., Yin, L., Martin, P. D., Yang, Z., Jiang, H., & Ahn, M.-J. (2015) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 33

Abstract PR07: AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: a Phase I study

Lee, D. H., Kim, D.-W., Ahn, M.-J., Cho, B. C., Lee, J. S., Ye, X., Yang, P., Jiang, H., & Yang, J. C.-H. (2015) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 7

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

Lee, D. H., Kim, H. R., Keam, B., Kato, K., Kuboki, Y., Gao, H., Yovine, A., Robbins, S. H., & Ahn, M. (2023) · Cancer Medicine

Esophageal Cancer Research and TreatmentCancer Immunotherapy and Biomarkers

Cited by 6